Navigation Links
Therapeutic cloning gets a boost with new research findings

San Antonio Germ cells, the cells which give rise to a mammal's sperm or eggs, exhibit a five to ten-fold lower rate of spontaneous point mutations than adult somatic cells, which give rise to the body's remaining cell types, tissues and organs. Despite their comparatively higher mutation rates, however, adult somatic cells are used as the donor cells in a cloning process called somatic cell nuclear transfer (SCNT). This made researchers wonder if cloning by SCNT leads to progeny with more mutations than their naturally conceived counterparts. Also, would cloned fetuses receive DNA programming predisposing them to develop mutations faster than natural fetuses of the same age?

Those scenarios are simply not likely, say researchers at The University of Texas at San Antonio, The University of Texas Health Science Center at San Antonio and The University of Hawaii at Honolulu's John A. Burns School of Medicine. The team, which spent more than five years analyzing mutation rates and types in cloned Big Blue mouse fetuses recently published its findings in the online Early Edition of the Proceedings of the National Academy of Sciences in a paper titled "Epigenetic regulation of genetic integrity is reprogrammed during cloning."

The paper offers the first direct demonstration that cloning does not lead to an increase in the frequency of point mutations.

John McCarrey, professor of cellular and molecular biology at UTSA and the study's principal investigator, suggests a "bottleneck effect" is partially responsible for the observations his team recorded. "To create a cloned fetus by somatic cell nuclear transfer, only one adult somatic cell -- one donor cell -- is needed," he explains. "Because a random cell population exhibits a low mutation rate overall and only one cell from that population is used for cloning, the likelihood is remote that the cell chosen to be cloned will transfer a genetic mutation to its cloned offspring. Therefore, the bottleneck effect limits the transfer of mutations from donor cells to cloned offspring."

Not only did the researchers find that SCNT does not lead to an increase in the frequency of point mutations in cloned mice, the team also found that naturally conceived fetuses and cloned fetuses that are the same age have similar rates of spontaneous mutation development. They attribute this finding to epigenetic reprogramming.

It is known in the scientific community that germ cells contain an epigenome, a programmed state of the genome, that keeps mutation rates low. They suggest this type of epigenome is found in germ cells because those cells are responsible for contributing genetic information to subsequent generations. Adult somatic cells (the donor cells in SCNT) have higher mutation rates and less stringent epigenetic programming to avoid mutations than germ cells, but offspring produced from somatic cells by cloning have mutation rates similar to those in offspring produced by natural reproduction, suggesting that the epigenome of an adult somatic cell is reprogrammed during cloning to maintain the genetic integrity of that cell's progeny.


Contact: Christi Fish
University of Texas at San Antonio

Related biology news :

1. Therapeutic hypothermia is promising strategy to minimize tissue damage
2. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
3. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
4. Magnetic nanoparticles navigate therapeutic genes through the body
5. New potential therapeutic target discovered for genetic disorder -- Barth syndrome
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
9. New therapeutic target identified for rheumatoid arthritis
10. Simple chemical procedure augments therapeutic potential of stem cells
11. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
Post Your Comments:
(Date:9/24/2015)... Publiceringsförbud fram till: ... Kerv ( ), det Londonbaserade ... första kontaktlösa betalningsring på i ett ... för massproduktion via crowdfunding.       ... Kerv-bärare kan göra direkta kontaktlösa betalningar ...
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
(Date:9/10/2015)... 10, 2015 Pursuant Health has collaborated ... create an interactive, image-based health risk assessment (HRA) ... kiosk.  The unique assessment quantifies user results into ... suggests an individual,s biological age based on personal ... by the kiosk. Comprised of age, ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... N.J. and SAN DIEGO ... and Mast Therapeutics, Inc. have agreed to collaborate in ... excipient-grade poloxamer 188 NF, marketed by BASF under the ... in a variety of pharmaceutical and biological applications, such ... 188 is the starting material for Mast,s lead product ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff ... the company’s fast growing clinical data solutions business. , Jeff Parr has spent the ... all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The New ... age children in the areas of Science, Technology, Engineering and Mathematics. The skill ... economy, and the program aims to increase the number of students who pursue ...
Breaking Biology Technology: